Press Releases
Search
-
31 Aug 2022
Financial Information
First-Half 2022 Results
The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on August 30 under the chairmanship of Alexandre Mérieux and approved the consolidated financial statements for the six months ended June 30, 2022.
-
22 Aug 2022
Antimicrobial Resistance
The SPECIFIC REVEAL® Rapid AST System has received Breakthrough Device Designation from the U.S. Food and Drug Administration
bioMérieux, a world leader in the field of in vitro diagnostics, today announces that the U.S. Food and Drug Administration (FDA) has granted its Breakthrough Device Designation for the SPECIFIC REVEAL® Rapid Antimicrobial Susceptibility Test (AST) System.
-
28 Jul 2022
Business & Solutions
bioMérieux receives FDA Clearance for NEPHROCHECK® test on VIDAS®
bioMérieux announced the FDA Clearance of VIDAS® NEPHROCHECK® assay to detect kidney stress in patients at risk of acute kidney injury (AKI).
-
07 Jul 2022
Pharma Quality Control
bioMérieux launches 3P® ENTERPRISE, an innovative solution for the pharma industry
bioMérieux, a world leader in the field of in vitro diagnostics, launches 3P® ENTERPRISE, an innovative solution designed to ensure environmental monitoring processes are fully efficient and under control at all times.
-
06 Jul 2022
Antimicrobial Resistance
Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
Boehringer Ingelheim, Evotec SE and bioMérieux announced today that they have formed a joint venture to create the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance (AMR).
-
19 May 2022
Antimicrobial Resistance
Closing of the acquisition of Specific Diagnostics
bioMérieux, a world leader in the field of in vitro diagnostics, announces that it has finalized the acquisition of Specific Diagnostics, a privately held U.S. based company that has developed a rapid antimicrobial susceptibility test (AST) system that delivers phenotypic AST directly from positive blood cultures.